283 related articles for article (PubMed ID: 33428282)
1. Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.
Lebwohl MG; Stein Gold L; Papp K; Han G; Pariser DM; Lin T; Harris S; Jacobson A
J Eur Acad Dermatol Venereol; 2021 May; 35(5):1152-1160. PubMed ID: 33428282
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.
Kircik LH; Papp KA; Stein Gold L; Harris S; Pharm TL; Pillai R
J Drugs Dermatol; 2019 Mar; 18(3):279-284.. PubMed ID: 30909333
[TBL] [Abstract][Full Text] [Related]
5. Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis.
Lebwohl MG; Stein Gold L; Del Rosso JQ; Green L; Jacobson A
J Dermatolog Treat; 2022 Jun; 33(4):2068-2074. PubMed ID: 34130581
[TBL] [Abstract][Full Text] [Related]
6. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
[TBL] [Abstract][Full Text] [Related]
8. Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
Stein Gold L; Kircik LH; Pariser D; Sugarman JL; Lin T; Kang R; Pillai R
J Drugs Dermatol; 2018 Aug; 17(8):863-868. PubMed ID: 30124725
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Sugarman JL; Weiss J; Tanghetti EA; Bagel J; Yamauchi PS; Stein Gold L; Lin T; Martin G; Pillai R; Israel R
J Drugs Dermatol; 2018 Aug; 17(8):855-861. PubMed ID: 30124724
[TBL] [Abstract][Full Text] [Related]
10. Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
Stein Gold L; Elewski B; Draelos Z; Jacobson A; Lin T
J Drugs Dermatol; 2020 May; 19(5):504-514. PubMed ID: 32484629
[TBL] [Abstract][Full Text] [Related]
11. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
[TBL] [Abstract][Full Text] [Related]
12. Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
Tanghetti EA; Bhatia N; Drew S; Jacobson A
J Drugs Dermatol; 2021 Aug; 20(8):829-836. PubMed ID: 34397206
[TBL] [Abstract][Full Text] [Related]
13. Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities.
Tyring S; Kircik LH; Yamauchi P; Jacobson A; Lin T
J Drugs Dermatol; 2020 Apr; 19(4):389-396. PubMed ID: 32272516
[TBL] [Abstract][Full Text] [Related]
14. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
Stein Gold L; Bagel J; Lebwohl M; Lin T; Martin G; Pillai R
J Drugs Dermatol; 2018 Dec; 17(12):1290-1296. PubMed ID: 30586261
[TBL] [Abstract][Full Text] [Related]
15. Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials.
Ramachandran V; Bertus B; Bashyam AM; Feldman SR
Ann Pharmacother; 2020 Sep; 54(9):872-878. PubMed ID: 32126800
[No Abstract] [Full Text] [Related]
16. Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion With a Ceramide-Containing Moisturizer in Adults With Psoriasis.
Kircik L; Jacobson A
J Drugs Dermatol; 2024 Feb; 23(2):50-53. PubMed ID: 38306148
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis.
Blauvelt A; Green LJ; Lebwohl MG; Yamauchi PS; Lin T; Martin G; Pillai R
J Drugs Dermatol; 2019 Mar; 18(3):297-299. PubMed ID: 30909352
[TBL] [Abstract][Full Text] [Related]
18. Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Patients With Skin of Color.
Alexis AF; Desai SR; Han G; Jacobson A
J Drugs Dermatol; 2021 Jul; 20(7):744. PubMed ID: 34232005
[TBL] [Abstract][Full Text] [Related]
19. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
[TBL] [Abstract][Full Text] [Related]
20. Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis.
Guenther L; Metelitsa A; Prajapati VH
Skin Therapy Lett; 2021 Nov; 26(6):1-3. PubMed ID: 34871475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
